C-reactive protein: interaction with the vascular endothelium and possible role in human atherosclerosis.
C-reactive protein (CRP) is the first acute phase protein that has been described in the literature. It is phylogenetically ancient and - with serum amyloid P - belongs to proteins named as "pentraxin". After being considered a marker of acute inflammation for several decades and fruitfully used in clinical practice, CRP has been recently considered as a potential contributor to inflammatory diseases including atherosclerosis as well as a marker of cardiovascular risk. With regard to the first topic, inflammation is now believed to represent the underlying mechanism leading to the formation of human atheroma and favouring both the destabilization of vulnerable plaques and the formation of occlusive thrombi. In this regard, numerous studies indicated that modest changes in circulating CRP levels, as detected by highly sensitive methods, can be extremely useful in predicting cardiovascular and perhaps cerebrovascular diseases in apparently healthy individuals as well as in patients affected by atherosclerosis. Subjects manifesting with identical low density cholesterol and/or blood pressure levels have different rates of cardiovascular accidents on the basis of different circulating CRP concentrations. In addition, women with identical cardiovascular risk profiles developed more type 2 diabetes in the presence of higher circulating CRP levels and thereby are expected to display divergent cardiovascular prognosis. Therefore, even slight changes in circulating CRP concentrations - assuming that blood is collected appropriately and CRP is measured with correct methods - could help clinicians in defining individual cardiovascular risk. In this review, we have firstly described the current understanding of the structure of CRP, its function, and interaction with the vascular endothelial cell. Then, we have discussed how to measure circulating CRP and the more recent findings on the suggested role of circulating CRP as a novel cardiovascular risk factor.
Ferri
Claudio
C
Department of Internal Medicine and Public Health, University of L'Aquila, L'Aquila, Italy. claudio.ferri@cc.univaq.it
Croce
Giuseppe
G
Cofini
Vincenza
V
De Berardinis
Giovanni
G
Grassi
Davide
D
Casale
Raffaele
R
Properzi
Giuliana
G
Desideri
Giovambattista
G
D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000150:complications / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D002097:C-Reactive Protein / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000378:metabolism; D004730:Endothelium, Vascular / Q000378:metabolism* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D011487:Protein Conformation; D018570:Risk Assessment; D012307:Risk Factors
D015415:Biomarkers; D002097:C-Reactive Protein